Vincere Biosciences Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$5M
- Investors
-
20
Vincere Biosciences General Information
Description
Developer of a biotechnology research platform designed to offer therapeutics for neurodegenerative disease. The company's platform is a patented biology simulation technology that integrates large-scale human genomic and biochemical data to facilitate research, clinical studies, and the creation of drugs that can restore mitochondrial quality, enabling medical researchers to access the drugs capable of treating Parkinson's disease painlessly.
Contact Information
Website
www.vincerebio.comCorporate Office
- 245 Main Street
- Floor 2
- Cambridge, MA 02142
- United States
Corporate Office
- 245 Main Street
- Floor 2
- Cambridge, MA 02142
- United States
Vincere Biosciences Timeline
Vincere Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Grant | 18-Nov-2025 | $5M | Completed | Generating Revenue | ||
| 11. Later Stage VC (Series A) | 01-Apr-2025 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series A1) | 16-Oct-2023 | Completed | Generating Revenue | |||
| 9. Grant | 25-Sep-2023 | Completed | Generating Revenue | |||
| 8. Grant | 29-Aug-2022 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series A) | 23-Sep-2021 | Completed | Generating Revenue | |||
| 6. Seed Round | 25-Nov-2020 | Completed | Generating Revenue | |||
| 5. Grant | 01-Apr-2020 | Completed | Generating Revenue | |||
| 4. Seed Round | 12-Sep-2019 | $1.5M | $1.5M | Completed | Generating Revenue | |
| 3. Accelerator/Incubator | 07-May-2019 | Completed | Generating Revenue |
Vincere Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 797,866 | $0.000100 | $0.94 | $0.94 | 1x | $0.94 | 6.76% | |
| Seed-1 | 903,608 | $0.000100 | $0.83 | $0.83 | 1x | $0.83 | 7.66% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Vincere Biosciences Comparisons
Industry
Financing
Details
Vincere Biosciences Competitors (3)
One of Vincere Biosciences’s 3 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Aspen Neuroscience | Formerly VC-backed | San Diego, CA | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA |
Vincere Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vincere Biosciences Patents
Vincere Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024509936-A | Usp30 inhibitors and their uses | Pending | 10-Mar-2021 | ||
| AU-2022234774-A1 | Usp30 inhibitors and uses thereof | Pending | 10-Mar-2021 | ||
| CA-3211571-A1 | Usp30 inhibitors and uses thereof | Pending | 10-Mar-2021 | ||
| EP-4305021-A1 | Usp30 inhibitors and uses thereof | Pending | 10-Mar-2021 | ||
| EP-4305021-A4 | Usp30 inhibitors and uses thereof | Pending | 10-Mar-2021 | C07D207/16 |
Vincere Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vincere Biosciences Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beiersdorf | Corporation | Minority | ||
| Beiersdorf Venture Capital | Corporate Venture Capital | Minority | ||
| Daewoong Pharmaceutical | Corporation | Minority | ||
| Kastor Capital | Venture Capital | Minority | ||
| Draper Associates | Venture Capital | Minority |
Vincere Biosciences FAQs
-
When was Vincere Biosciences founded?
Vincere Biosciences was founded in 2018.
-
Where is Vincere Biosciences headquartered?
Vincere Biosciences is headquartered in Cambridge, MA.
-
What is the size of Vincere Biosciences?
Vincere Biosciences has 9 total employees.
-
What industry is Vincere Biosciences in?
Vincere Biosciences’s primary industry is Drug Discovery.
-
Is Vincere Biosciences a private or public company?
Vincere Biosciences is a Private company.
-
What is Vincere Biosciences’s current revenue?
The current revenue for Vincere Biosciences is .
-
How much funding has Vincere Biosciences raised over time?
Vincere Biosciences has raised $16.3M.
-
Who are Vincere Biosciences’s investors?
Beiersdorf, Beiersdorf Venture Capital, Daewoong Pharmaceutical, Kastor Capital, and Draper Associates are 5 of 20 investors who have invested in Vincere Biosciences.
-
Who are Vincere Biosciences’s competitors?
Voyager Therapeutics, Aspen Neuroscience, and Denali Therapeutics are competitors of Vincere Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
